Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The c… Read more
Genome & Company (314130) - Total Liabilities
Latest total liabilities as of September 2025: ₩41.38 Billion KRW
Based on the latest financial reports, Genome & Company (314130) has total liabilities worth ₩41.38 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Genome & Company - Total Liabilities Trend (2021–2024)
This chart illustrates how Genome & Company's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Genome & Company Competitors by Total Liabilities
The table below lists competitors of Genome & Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Priner Serviços Industriais S.A
SA:PRNR3
|
Brazil | R$1.07 Billion |
|
Prime Mining Corp
OTCQX:PRMNF
|
USA | $1.56 Million |
|
Acres Commercial Realty Corp
NYSE:ACR
|
USA | $1.25 Billion |
|
Karyopharm Therapeutics Inc
NASDAQ:KPTI
|
USA | $365.49 Million |
|
1Stdibs.Com Inc
NASDAQ:DIBS
|
USA | $38.53 Million |
|
Garofalo Health Care S.p.A
F:GHC
|
Germany | €507.83 Million |
|
Guangdong Jushen Logistics Co Ltd
SHE:001202
|
China | CN¥1.03 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Genome & Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Genome & Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Genome & Company (2021–2024)
The table below shows the annual total liabilities of Genome & Company from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩99.02 Billion | -0.61% |
| 2023-12-31 | ₩99.63 Billion | +31.61% |
| 2022-12-31 | ₩75.70 Billion | +217.86% |
| 2021-12-31 | ₩23.82 Billion | -- |